The NCI Cancer Center Support Grant requires community outreach and engagement, but the design and implementation of COE programs, as well as staff training, are largely left to individual institutions.
The world of cancer treatments continues to evolve, and for those diagnosed with blood cancers, a new option can be found in menin inhibitors—the latest form of targeted therapy in advanced acute leukemia.Â
Krish Patel was appointed director of lymphoma research at Sarah Cannon Research Institute.
Robert Schnoll, Penn Medicine’s Abramson Cancer Center’s associate director for population science, was named the John H. Glick, MD Professor in Cancer Research. Schnoll is also the director of the Center for Interdisciplinary Research on Nicotine Addiction, a senior fellow in the Penn Center for Public Health, and co-director of the Community Research and Engagement Core at the Penn Center for AIDS Research.
William K. Oh was appointed as service medical director of Smilow Cancer Hospital at Greenwich Hospital, as well as director of precision medicine for Yale Cancer Center and Smilow Cancer Hospital.
Roy S. Herbst (middle) receives his award at the Innovation Gala of The Chemotherapy+ Foundation, with Robert Winn (left), director and Lipman Chair in Oncology at VCU Massey Comprehensive Cancer Center, and Katerina Politi (right), scientific director of YCC’s Center for Thoracic Cancers.Roy S. Herbst was awarded the Ezra Greenspan Award at the Innovation Gala of The Chemotherapy+ Foundation on Nov. 19 in New York City.Â
Jupiter Bioventures, a biotechnology venture foundry that builds science-driven therapeutics companies, announced the closing of a $70 million initial financing.
The U.S. Department of Energy’s Argonne National Laboratory will use its world-leading capabilities in artificial intelligence and high-performance computing to research novel ways to fight cancer and advance vaccine discovery.Â
The University of Cincinnati Cancer Center was granted $2.3 million from NCI to develop a technique to visualize where genetically modified immune cells go in the body after being administered to patients with cancer.
Marking a new era of non-invasive medical interventions, the Northwell Health Cancer Institute is investing $1.2 million in the development of cutting-edge histotripsy technology to treat some liver cancer tumors without surgery. This innovative approach uses targeted ultrasound beams to create microbubbles within tumors, effectively disrupting and destroying diseased cells without the need for incisions.
